title: Bevacizumab reverses cerebral radiation necrosis.
authors.affiliation: Brain Tumor Center & Neuro-Oncology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Eric T
authors.initials: ET
authors.lastname: Wong
authors.forename: Mark
authors.initials: M
authors.lastname: Huberman
authors.forename: Xing-Qi
authors.initials: XQ
authors.lastname: Lu
authors.forename: Anand
authors.initials: A
authors.lastname: Mahadevan
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001921:Brain / Q000528:radiation effects*; D001930:Brain Injuries / Q000188:drug therapy*; D002277:Carcinoma / Q000150:complications / Q000532:radiotherapy*; D005260:Female; D034381:Hearing Loss; D006801:Humans; D008279:Magnetic Resonance Imaging; D009303:Nasopharyngeal Neoplasms / Q000150:complications / Q000532:radiotherapy*; D009336:Necrosis / Q000188:drug therapy*; D011832:Radiation Injuries / Q000188:drug therapy*; D050397:Radiotherapy, Intensity-Modulated; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab